Key result
Higher miR-483-5p expression predicts VTE in lung cancer, with highest accuracy in high BMI patients.
Why the study?
The roles of microRNAs in venous thromboembolism among lung cancer patients remain scarce and need further evaluation.
Does miR-483-5p expression predict venous thromboembolism onset in patients with lung cancer?
Case-Control (n=170)
Does miR-483-5p expression predict venous thromboembolism onset in patients with lung cancer?
Elevated miR-483-5p expression may serve as an independent biomarker for predicting venous thromboembolism in lung cancer patients, particularly those with high BMI.
Elevated miR-483-5p may support VTE risk stratification in lung cancer; leaves open prospective validation before clinical use.
BACKGROUND: Venous thromboembolism (VTE) is a common complication in patients with lung cancer. The important roles of microRNAs (miRNAs) in VTE have emerged, however, studies about the roles of miRNAs in VTE remain scarce. This study aimed to measure the expression of miR-483-5p in lung cancer patients with VTE, evaluate whether miR-483-5p could predict VTE onset in patients, and further evaluate its predictive value in patients with different BMI values. METHODS: A total of 170 patients with lung cancer were recruited in this study, including 70 patients with VTE, and 110 patients with non-VTE. The expression of miR-483-5p was detected by quantitative real time PCR. Receiver operating characteristic analysis was used to screen VTE patients from non-VTE patients. Whether miR-483-5p was independently associated with VTE onset in lung cancer patients was evaluated by univariate and multivariate logistic regression analyses. RESULTS: miR-483-5p was higher in VTE patients than that in non-VTE patients. miR-483-5p was correlated with body mass index (BMI), hypertension, C-reactive protein (CRP), and platelet count in VTE patients. In addition, miR-483-5p had high diagnostic value to differentiate between VTE patients and non-VTE patients and served as an independent biomarker in predicting the VTE onset in lung cancer patients. Moreover, miR-483-5p had the highest diagnostic accuracy to screen VTE patients from non-VTE patients in patients with high BMI values. CONCLUSION: miR-483-5p, increased in VTE patients, can independently predict VTE onset in lung cancer patients especially in patients with high BMI values.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted a case-control in Lung cancer (n=170). miR-483-5p expression vs. Non-VTE patients was evaluated on Venous thromboembolism (VTE) onset. Higher expression of miR-483-5p independently predicted venous thromboembolism onset in patients with lung cancer, with the highest diagnostic accuracy in patients with high BMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: